Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Advertisement
Advertisement
Trending on OncLive
1
UT MD Anderson Honors Visionary Leadership of Peter Pisters, MD, MHCM, Following Retirement Announcement; Shares Transition Plans
2
China's NMPA Approves Fanregratinib for Pretreated FGFR2+ Intrahepatic Cholangiocarcinoma
3
How RP1 Plus Nivolumab Overcame Two CRLs to Win Approval in Melanoma
4
OncLive Weekly News Quiz (8/28/2026): Did You Miss Key Pancreatic, Gastric, Breast, and Biliary Tract Cancer Updates?
5